MAZE

Maze Therapeutics Inc

Oct 06 • 04:00PM ET

27.52

+0.41 1.51 %

Healthcare • Biotechnology • USA • NASD

Held by: IWM IWN VTI DWAS SCHA VXF IWC VTWO SCHB SBIO

Index	RUT	P/E	-	EPS (ttm)	-1.68	Insider Own	55.40%	Shs Outstand	43.85M	Perf Week	9.21%
Market Cap	1.21B	Forward P/E	-	EPS next Y	-2.88	Insider Trans	-0.09%	Shs Float	19.56M	Perf Month	73.30%
Enterprise Value	967.25M	PEG	-	EPS next Q	-0.71	Inst Own	35.46%	Short Float	8.35%	Perf Quarter	82.74%
Income	-73.80M	P/S	482.71	EPS this Y	-355.88%	Inst Trans	-8.15%	Short Ratio	3.82	Perf Half Y	203.42%
Sales	2.50M	P/B	4.60	EPS next Y	9.86%	ROA	-	Short Interest	1.63M	Perf YTD	72.54%
Book/sh	5.98	P/C	4.56	EPS next 5Y	-	ROE	-	52W High	28.37 -3.00%	Perf Year	-
Cash/sh	6.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	-26.12%	52W Low	6.71 310.13%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-13.04%	Volatility	7.10% 9.85%	Perf 5Y	-
Dividend TTM	-	EV/Sales	386.90	EPS Y/Y TTM	-	Oper. Margin	-5033.20%	ATR (14)	1.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.63	Sales Y/Y TTM	-	Profit Margin	-2951.92%	RSI (14)	74.32	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.63	EPS Q/Q	-3.52%	SMA20	13.90%	Beta	-	Target Price	37.83
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	50.88%	Rel Volume	0.72	Prev Close	27.11
Employees	125	LT Debt/Eq	0.08	Earnings	Aug 12 AMC	SMA200	102.33%	Avg Volume	427.34K	Price	27.52
IPO	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.89% -100.00%	Trades		Volume	311,278	Change	1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	BTIG Research	Buy	$30
Jul-23-25	Initiated	H.C. Wainwright	Buy	$34
Jul-08-25	Initiated	Wedbush	Outperform	$17

Oct-06-25 07:00AM	Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors (GlobeNewswire)
Sep-19-25 04:02PM	Maze Therapeutics, Inc. (MAZE): A Bull Case Theory (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-12-25 07:45AM	Maze reports positive results from Phase I trial of PKU and CKD treatment (Clinical Trials Arena) -6.07%
06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
09:29AM	Loading…
Sep-11-25 09:29AM	Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results (Investor's Business Daily) +54.81%
07:35AM	Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement (GlobeNewswire)
07:30AM	Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) (GlobeNewswire)
Sep-02-25 07:00AM	Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer (GlobeNewswire) +5.73%
Aug-12-25 04:01PM	Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jul-31-25 07:46AM	Venture firm Frazier closes $1.3B fund for early-stage biotech investing (BioPharma Dive)
Jul-10-25 04:05PM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-29-25 07:30AM	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +6.01%
May-14-25 04:01PM	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones (GlobeNewswire) -8.11%
May-13-25 07:30AM	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
07:30AM	Loading…
Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SCHELLER RICHARD H	Director	Sep 15 '25	Sale	22.37	20,744	464,035	0	Sep 16 04:26 PM
RICHARD SCHELLER	Director	Sep 15 '25	Proposed Sale	22.37	20,744	464,035		Sep 15 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your FINVIZ experience